Breaking News

Financial Report: AMRI

By Kristin Brooks | February 12, 2014

Achieves record contract revenues

AMRI
 
4Q Revenues: $67.1 million (flat)

4Q Earnings: $4.5 million (+137%)

FY Revenues: $246.6 million (+9%)

FY Earnings: $12.7 million (loss of $3.8 million FY12)

Comments: Contract revenue for the quarter was a record $59.7 million, up 1%. Royalty revenue in the quarter was $7.4 million, down 9%, and includes royalties from the Allegra products as well as $2.3 million from sales of certain amphetamine salts sold by Actavis. Contract revenue for the year was a record $210.0 million, up 11%, while royalty revenue was $36.6 million, up 2%. Discovery Services and Development / Small Scale Manufacturing (DDS) contract revenue for the quarter was $18.4 million, down 12%, with lower revenue in Development / Small Scale Manufacturing, partially offset by higher Discovery Services revenue, and for the year was $77.4 million, up 5%. Large Scale Manufacturing revenue for the quarter was $41.3 million, up 8%, and $132.6 million for the year, up 14%.
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.